In brief

• AstraZeneca reported $16.21 billion in revenue in Q3, exceeding Wall Street's forecasts

• A new restructuring plan aims to generate $1.5 billion in annual savings by 2029.

• Can AI make the pharmaceutical company's $80,0000 billion revenue target easier to achieve?

Read the original story “Covid vaccine giant AstraZeneca stock rises 7 percent. What's behind it?” by Jakub Dziadkowiec on fi.beincrypto.com